Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

InMed Pharmaceuticals (INM) Accumulated Depreciation & Amortization (2021 - 2025)

Historic Accumulated Depreciation & Amortization for InMed Pharmaceuticals (INM) over the last 5 years, with Q2 2025 value amounting to $1.3 million.

  • InMed Pharmaceuticals' Accumulated Depreciation & Amortization fell 125.07% to $1.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.3 million, marking a year-over-year decrease of 125.07%. This contributed to the annual value of $1.3 million for FY2025, which is 125.07% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $1.3 million for Q2 2025, which was down 125.07% from $1.2 million recorded in Q1 2025.
  • InMed Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $1.4 million for Q2 2024, and its period low was $244261.0 during Q3 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $976752.5 (2023), whereas its average is $877792.9.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first soared by 15315.26% in 2022, then tumbled by 185.55% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $320520.0 in 2021, then soared by 123.64% to $716800.0 in 2022, then soared by 56.84% to $1.1 million in 2023, then grew by 1.43% to $1.1 million in 2024, then rose by 17.38% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q2 2025, $1.2 million for Q1 2025, and $1.1 million during Q4 2024.